Using gene therapy to protect and restore cartilage

Christopher H Evans, S. C. Ghivizzani, P. Smith, F. D. Shuler, Z. Mi, P. D. Robbins

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Numerous gene products have the potential to help protect cartilage from degradation and to repair cartilage that has become damaged as a result of disease or injury. The genes that encode these products thus may serve as chondroprotective and chondroregenerative medicines. To bring these agents into clinical use, it is necessary to screen candidate genes for efficacy under in vitro and in vivo conditions, to determine the best cells to target, and to develop appropriate gene transfer technologies. As discussed in the current review, progress has been made in each of these areas. Various viral and nonviral vectors are able to deliver genes to synoviocytes, articular chondrocytes, and mesenchymal stem cells. There also is evidence to suggest that ex vivo and in vivo approaches can be used for gene transfer to articular cartilage, synovium, and meniscus. Moreover various cytokine antagonists and growth factors have been shown to protect cartilage and stimulate chondrogenesis. In vivo methods and strategies that target synovium may be useful in a chondroprotective mode but because they do not increase the number of chondrogenic cells within lesions, they may be ill-equipped to repair large defects. Ex vivo methods however, provide cells and genes. It also is important to distinguish the treatment of isolated lesions occurring as a result of injury from the treatment of lesions resulting from underlying disease processes. Additional development of these approaches should result in clinically useful generic methods for the protection and regeneration of cartilagenous tissues.

Original languageEnglish (US)
JournalClinical Orthopaedics and Related Research
Issue number379 SUPPL.
StatePublished - 2000
Externally publishedYes

Fingerprint

Genetic Therapy
Cartilage
Genes
Synovial Membrane
Technology Transfer
Chondrogenesis
Wounds and Injuries
Articular Cartilage
Chondrocytes
Mesenchymal Stromal Cells
Regeneration
Intercellular Signaling Peptides and Proteins
Cell Count
Joints
Cytokines
Therapeutics

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine
  • Surgery

Cite this

Evans, C. H., Ghivizzani, S. C., Smith, P., Shuler, F. D., Mi, Z., & Robbins, P. D. (2000). Using gene therapy to protect and restore cartilage. Clinical Orthopaedics and Related Research, (379 SUPPL.).

Using gene therapy to protect and restore cartilage. / Evans, Christopher H; Ghivizzani, S. C.; Smith, P.; Shuler, F. D.; Mi, Z.; Robbins, P. D.

In: Clinical Orthopaedics and Related Research, No. 379 SUPPL., 2000.

Research output: Contribution to journalArticle

Evans, CH, Ghivizzani, SC, Smith, P, Shuler, FD, Mi, Z & Robbins, PD 2000, 'Using gene therapy to protect and restore cartilage', Clinical Orthopaedics and Related Research, no. 379 SUPPL..
Evans CH, Ghivizzani SC, Smith P, Shuler FD, Mi Z, Robbins PD. Using gene therapy to protect and restore cartilage. Clinical Orthopaedics and Related Research. 2000;(379 SUPPL.).
Evans, Christopher H ; Ghivizzani, S. C. ; Smith, P. ; Shuler, F. D. ; Mi, Z. ; Robbins, P. D. / Using gene therapy to protect and restore cartilage. In: Clinical Orthopaedics and Related Research. 2000 ; No. 379 SUPPL.
@article{be06a28ec6054402afcefb0fed279278,
title = "Using gene therapy to protect and restore cartilage",
abstract = "Numerous gene products have the potential to help protect cartilage from degradation and to repair cartilage that has become damaged as a result of disease or injury. The genes that encode these products thus may serve as chondroprotective and chondroregenerative medicines. To bring these agents into clinical use, it is necessary to screen candidate genes for efficacy under in vitro and in vivo conditions, to determine the best cells to target, and to develop appropriate gene transfer technologies. As discussed in the current review, progress has been made in each of these areas. Various viral and nonviral vectors are able to deliver genes to synoviocytes, articular chondrocytes, and mesenchymal stem cells. There also is evidence to suggest that ex vivo and in vivo approaches can be used for gene transfer to articular cartilage, synovium, and meniscus. Moreover various cytokine antagonists and growth factors have been shown to protect cartilage and stimulate chondrogenesis. In vivo methods and strategies that target synovium may be useful in a chondroprotective mode but because they do not increase the number of chondrogenic cells within lesions, they may be ill-equipped to repair large defects. Ex vivo methods however, provide cells and genes. It also is important to distinguish the treatment of isolated lesions occurring as a result of injury from the treatment of lesions resulting from underlying disease processes. Additional development of these approaches should result in clinically useful generic methods for the protection and regeneration of cartilagenous tissues.",
author = "Evans, {Christopher H} and Ghivizzani, {S. C.} and P. Smith and Shuler, {F. D.} and Z. Mi and Robbins, {P. D.}",
year = "2000",
language = "English (US)",
journal = "Clinical Orthopaedics and Related Research",
issn = "0009-921X",
publisher = "Springer New York",
number = "379 SUPPL.",

}

TY - JOUR

T1 - Using gene therapy to protect and restore cartilage

AU - Evans, Christopher H

AU - Ghivizzani, S. C.

AU - Smith, P.

AU - Shuler, F. D.

AU - Mi, Z.

AU - Robbins, P. D.

PY - 2000

Y1 - 2000

N2 - Numerous gene products have the potential to help protect cartilage from degradation and to repair cartilage that has become damaged as a result of disease or injury. The genes that encode these products thus may serve as chondroprotective and chondroregenerative medicines. To bring these agents into clinical use, it is necessary to screen candidate genes for efficacy under in vitro and in vivo conditions, to determine the best cells to target, and to develop appropriate gene transfer technologies. As discussed in the current review, progress has been made in each of these areas. Various viral and nonviral vectors are able to deliver genes to synoviocytes, articular chondrocytes, and mesenchymal stem cells. There also is evidence to suggest that ex vivo and in vivo approaches can be used for gene transfer to articular cartilage, synovium, and meniscus. Moreover various cytokine antagonists and growth factors have been shown to protect cartilage and stimulate chondrogenesis. In vivo methods and strategies that target synovium may be useful in a chondroprotective mode but because they do not increase the number of chondrogenic cells within lesions, they may be ill-equipped to repair large defects. Ex vivo methods however, provide cells and genes. It also is important to distinguish the treatment of isolated lesions occurring as a result of injury from the treatment of lesions resulting from underlying disease processes. Additional development of these approaches should result in clinically useful generic methods for the protection and regeneration of cartilagenous tissues.

AB - Numerous gene products have the potential to help protect cartilage from degradation and to repair cartilage that has become damaged as a result of disease or injury. The genes that encode these products thus may serve as chondroprotective and chondroregenerative medicines. To bring these agents into clinical use, it is necessary to screen candidate genes for efficacy under in vitro and in vivo conditions, to determine the best cells to target, and to develop appropriate gene transfer technologies. As discussed in the current review, progress has been made in each of these areas. Various viral and nonviral vectors are able to deliver genes to synoviocytes, articular chondrocytes, and mesenchymal stem cells. There also is evidence to suggest that ex vivo and in vivo approaches can be used for gene transfer to articular cartilage, synovium, and meniscus. Moreover various cytokine antagonists and growth factors have been shown to protect cartilage and stimulate chondrogenesis. In vivo methods and strategies that target synovium may be useful in a chondroprotective mode but because they do not increase the number of chondrogenic cells within lesions, they may be ill-equipped to repair large defects. Ex vivo methods however, provide cells and genes. It also is important to distinguish the treatment of isolated lesions occurring as a result of injury from the treatment of lesions resulting from underlying disease processes. Additional development of these approaches should result in clinically useful generic methods for the protection and regeneration of cartilagenous tissues.

UR - http://www.scopus.com/inward/record.url?scp=0033775224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033775224&partnerID=8YFLogxK

M3 - Article

C2 - 11039771

AN - SCOPUS:0033775224

JO - Clinical Orthopaedics and Related Research

JF - Clinical Orthopaedics and Related Research

SN - 0009-921X

IS - 379 SUPPL.

ER -